The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010Is glucose metabolism perturbed in PD?
Objective/Rationale:
Glucose metabolism is of central importance in maintaining the anti-oxidant ability of neurons to protect themselves from internal and external damage. When glucose metabolism is... -
Rapid Response Innovation Awards, 2010Immuno-PCR Detection of Alpha-Synuclein Phosphorylated at Serine-129 as PD Biomarker
Objective/Rationale:
At present, the definite diagnosis of PD can be made only after death by examining the pathology in brain of deceased patients. Diagnosis assesses the presence of clumps within... -
Rapid Response Innovation Awards, 2010Increased Dopamine Transporter Function as an Early Phenotype of PD, Prior to Dopamine Neuron Cell Death
Objective/Rationale:
Since the identification of a number of Parkinson’s disease genes in humans, much effort has been spent at developing pre-clinical models of the disease. However, most genetic pre... -
Novel Hypotheses in Parkinson's Disease, 2010Gait disturbances in Parkinson's disease: new links to alpha-synuclein pathology
Objective/Rationale:
Gait disturbances in PD are characteristic of advanced Parkinson’s disease (PD); they are extremely disabling to the patient and can frequently lead to patient falls, fractures... -
Novel Hypotheses in Parkinson's Disease, 2010Identifying and Localizing Toxic Oligomeric A-Syn with Morphology Specific Nanobodies
Objective/Rationale:
Aggregation and deposition of the protein, a-synuclein (a-syn), has been strongly correlated with PD and other related neurodegenerative disorders. The a-syn protein occurs in a... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Determining Pharmacodynamic Biomarkers of LRRK2 Activity in Lymphocytes
Objective/Rationale:
Therapeutic strategies targeting aberrant LRRK2 activity hold great promise for the treatment of familial LRRK2 mutant and perhaps idiopathic PD. Development of pharmacodynamic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.